







Item 8.01. Other Events.

On September 25, 2018 TG Therapeutics, Inc. (“TG” or the “Company”) issued a press release in which it announced an update regarding the UNITY-CLL Phase 3 trial. TG also announced that on Tuesday, September 25, 2018 at 8:30am ET, the Company would host an investor conference call to discuss the update to the UNITY-CLL trial. A copy of the press release is being filed as Exhibit 99.1 and incorporated in this Item by reference.

Item 9.01 Financial Statements And Exhibits.

(d) Exhibits.

99.1 Press Release, dated September 25, 2018.



SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

TG Therapeutics, Inc.  
(Registrant)

Date: September 25, 2018

By: /s/ Sean A. Power  
Sean A. Power  
Chief Financial Officer